Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
Open Access
- 30 November 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (2) , 227-231
Abstract
Infections in critically ill patients continue to result in unacceptably high morbidity and mortality. Although few data exist for correlating antibiotic exposure with outcome, antibiotic dosing is likely to be highly important for maximizing resolution of infection in many patients. The practical and financial difficulties of performing pharmacokinetic (PK) studies in critically ill patients mean that analyses to maximize data such as Monte Carlo simulation (MCS) are highly valuable. MCS uses computer software to perform virtual clinical trials. The building blocks for MCS are: firstly, a robust population PK model from the patient population of interest; secondly, descriptors of the effect of covariates that influence the PK parameters; thirdly, description of the susceptibility of bacteria to the antibiotic and finally a PK/pharmacodynamic (PD) target associated with antibiotic efficacy. Probability of target attainment (PTA) outputs can then be generated that describe the proportion of patients that will achieve a pre-specified PD target for an MIC distribution. Such analyses can then inform dosing requirements, which can be used to have a high likelihood of achieving PK/PD targets for organisms with different MICs. In this issue of JAC, Zelenitsky et al. provide a very useful example of MCS for interpreting the optimal methods for dosing meropenem, piperacillin/tazobactam, cefepime and ceftobiprole in critically ill patients.Keywords
This publication has 23 references indexed in Scilit:
- Intensity of Continuous Renal-Replacement Therapy in Critically Ill PatientsNew England Journal of Medicine, 2009
- Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsInternational Journal of Antimicrobial Agents, 2008
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- Relationship between Fluoroquinolone Area under the Curve:Minimum Inhibitory Concentration Ratio and the Probability of Eradication of the Infecting Pathogen, in Patients with Nosocomial PneumoniaThe Journal of Infectious Diseases, 2004
- Adult-population incidence of severe sepsis in Australian and New Zealand intensive care unitsIntensive Care Medicine, 2004
- Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'Nature Reviews Microbiology, 2004
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003
- Inadequate Antimicrobial Treatment of InfectionsChest, 1999
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993